announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist
Alpha Arbutin:Lightens dark spots and discoloration
Two newer GLP-1 drugs are also currently in trials and expected to reach the market, which Moni said could further drive down prices on existing medications
Nitric oxide exerts protective effects against bleomycin-induced pulmonary fibrosis in mice
Liposomal vitamin C offers higher bioavailability, better tissue penetration, and fewer gastric side effectsespecially important for long-term use
It can be useful when the skin looks tired, dry, or uneven